RYTM News and Press, Rhythm Pharmaceuticals Inc. From 11/08/22

-- Previously disclosed data demonstrated statistically significant and clinically meaningful reductions in weight and hunger in patients with Bardet-Biedl syndrome -- BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharma...

-- U.S. launch of IMCIVREE ® (setmelanotide) for Bardet-Biedl Syndrome progresses with strong demand with more than 120 prescriptions since FDA approval -- -- EC authorization for IMCIVREE expanded to include BBS; UK launch in POMC and LEPR deficiencies und...

-- Analyses of Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) in children with BBS showed a significant positive correlation between degree of hyperphagia and body mass index (BMI) -- -- 84% of patients with BBS in Phase 3 clinical trial showed clinical benefit o...

-- Phase 3 clinical trial design reflects feedback obtained during recent discussions with FDA -- -- 89 percent (16 of 18) patients achieved primary endpoint with a BMI decrease greater than 5 percent at 16 weeks on setmelanotide therapy ( P<0.0001) – -- Long...

Commercial-stage biotech Rhythm Pharmaceuticals ( NASDAQ: RYTM ) added ~5% pre-market Tuesday after announcing that the FDA issued Breakthrough Therapy Designation for its lead candidate setmelanotide as a treatment for hypothalamic obesity. Setmelanotide, marketed as ...

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathw...

-- Rhythm to review data on webcast conference call on November 2, 2022 at 8:30 a.m. ET – -- Rhythm to report 3Q 2022 earnings on November 8, 2022 at 8:00 a.m. ET -- BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-...

-- Approximately 100 European health care professionals invited to discuss recent scientific developments in rare pathway-related obesities -- -- Rhythm presents analysis of Phase 2 Basket Study evaluating setmelanotide in patients with obesity and MC4R variants -- BOSTON, O...

Summary Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach. Biotechs benefit if a...

Summary Today, we circle back on Rhythm Therapeutics for the first time in over a year and a half. The company continues to advance its main asset Imcivree across multiple indications and recently addressed its near-term financing needs. The stock is up some 125% in 2022 on th...